31 results on '"Han, Seung Hyeok"'
Search Results
2. Body weight fluctuation is associated with rapid kidney function decline.
- Author
-
Joo YS, Nam KH, Jhee JH, Yun HR, Lee S, Han SH, Yoo TH, Kang SW, and Park JT
- Subjects
- Cohort Studies, Glomerular Filtration Rate, Humans, Prospective Studies, Risk Factors, Body Weight physiology, Kidney physiopathology, Kidney Diseases etiology, Kidney Diseases physiopathology
- Abstract
Objective: This study aimed to evaluate the effects of body weight fluctuations on kidney function deterioration in a prospective cohort of individuals with normal kidney function., Methods: Data were obtained from the Korean Genome and Epidemiology Study. Body weight fluctuations were determined using average successive variability (ASV), which was defined as the average absolute body weight change using repeated measurements for all participants. The decline of the estimated glomerular filtration rate (eGFR) over time was calculated using linear regression analysis of serial eGFR measurements for each patient. Rapid eGFR decline was defined as an average eGFR decline > 3 mL/min/1.73 m
2 per year., Results: A total of 6,790 participants were analyzed. During a median follow-up of 11.7 years, rapid eGFR decline was observed in 913 (13.4%) participants. When the participants were categorized into tertiles according to ASV, rapid eGFR decline was more prevalent in the highest ASV tertile group than in the lowest. Analyses using multiple logistic regression models revealed that the risk of rapid eGFR decline was increased in the highest ASV tertile group compared with the lowest (odds ratio: 1.66)., Conclusions: Body weight fluctuations were significantly associated with an increased risk of rapid kidney function decline in participants with normal kidney function., (© 2021 The Obesity Society.)- Published
- 2022
- Full Text
- View/download PDF
3. C1q nephropathy in adults is a form of focal segmental glomerulosclerosis in terms of clinical characteristics.
- Author
-
Kim K, Son HE, Ryu JY, Lee H, Han SH, Ryu DR, Paik JH, Kim S, Na KY, Chae DW, Chin HJ, and Oh SW
- Subjects
- Adult, Biopsy, Cohort Studies, Female, Follow-Up Studies, Glomerulosclerosis, Focal Segmental drug therapy, Glomerulosclerosis, Focal Segmental metabolism, Humans, Kidney drug effects, Kidney Diseases drug therapy, Kidney Diseases metabolism, Kidney Failure, Chronic pathology, Male, Middle Aged, Nephrosis, Lipoid drug therapy, Outcome Assessment, Health Care methods, Outcome Assessment, Health Care statistics & numerical data, Republic of Korea, Complement C1q metabolism, Glomerulosclerosis, Focal Segmental pathology, Kidney pathology, Kidney Diseases pathology, Nephrosis, Lipoid pathology
- Abstract
Although C1q nephropathy (C1qN) was introduced three decades ago, the clinical significance and renal outcomes of C1qN remain unclear. This study aimed to evaluate the clinical characteristics of C1qN, including renal outcomes, by performing a matched comparison within a multicenter cohort. We enrolled 6,413 adult patients who underwent kidney biopsy between January 2000 and January 2018 at three tertiary hospitals in Korea. We compared the clinical characteristics of 23 patients with C1qN with those of patients with focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD) who were matched by age, sex, diabetic status, and a period of biopsy. Histological and clinical parameters in patients with C1qN were also evaluated according to the different pathological phenotypes. For a mean follow-up period of 92 months, 4 patients with C1qN (17.4%) developed end-stage renal disease (ESRD). None of the matched patients with MCD had ESRD, but 7 (30.4%) of patients with FSGS progressed to ESRD, which was not different from that of C1qN patients (p = 0.491). Laboratory and pathological findings, except segmental glomerulosclerosis, were not notably different between FSGS and C1qN. The presence of segmental glomerulosclerosis, mesangial hypercellularity, and podocyte effacement did not affect both the short- and long-term renal outcomes in patients with C1qN. Our study showed that the renal outcomes of C1qN are comparable with those of FSGS, and not with MCD. Specific pathological findings, including segmental glomerulosclerosis in C1qN, were not associated with renal outcomes, which may suggest homogeneity in the clinical features of C1qN., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
4. Severe vitamin D deficiency is a risk factor for renal hyperfiltration.
- Author
-
Jhee JH, Nam KH, An SY, Cha MU, Lee M, Park S, Kim H, Yun HR, Kee YK, Park JT, Han SH, Kang SW, and Yoo TH
- Subjects
- Adult, Diabetes Complications complications, Female, Humans, Hypertension complications, Kidney physiopathology, Kidney Diseases etiology, Male, Middle Aged, Nutrition Surveys, Renal Insufficiency, Chronic epidemiology, Renal Insufficiency, Chronic etiology, Renal Insufficiency, Chronic physiopathology, Republic of Korea epidemiology, Risk, Vitamin D analogs & derivatives, Vitamin D blood, Vitamin D Deficiency blood, Vitamin D Deficiency epidemiology, Glomerular Filtration Rate physiology, Kidney Diseases epidemiology, Kidney Diseases physiopathology, Vitamin D Deficiency complications
- Abstract
Background: Vitamin D deficiency is associated with renal progression in chronic kidney disease. Moreover, improvement of clinical outcomes after vitamin D supplementation has been reported in the diabetic and chronic kidney disease population., Objective: We investigated the association between renal hyperfiltration (RHF) and vitamin D status in a relatively healthy population., Design: Data were retrieved from the Korean NHANES, a nationwide population-based cross-sectional study from 2008 to 2015. Overall, 33,210 subjects with normal renal function were included in the final analysis. Severe vitamin D deficiency was defined as serum 25-hydroxyvitamin D concentration <10 ng/mL. RHF was defined as estimated glomerular filtration rate with residual in the >95th percentile after adjustment for age, sex, height, weight, and history of hypertension or diabetes., Results: The mean ± SD age of subjects was 48.1 ± 15.9 y, and the number of women was 18,779 (56.5%). Estimated glomerular filtration rate was negatively associated with serum 25-hydroxyvitamin D concentrations in multivariable linear regression analysis (β: -0.02; 95% CI: -0.02, -0.01; P < 0.001). Furthermore, 1637 (4.9%) subjects were categorized into the RHF group, and the prevalence of RHF was significantly higher in the severe vitamin D deficiency group than in the sufficiency group (5.8% compared with 5.0%, P < 0.001). In a multivariable logistic regression model, severe vitamin D deficiency was a significant risk factor for RHF (OR: 2.41; 95% CI, 1.72, 3.43; P < 0.001)., Conclusions: Severe vitamin D deficiency is significantly associated with increasing prevalence of RHF in a relatively healthy adult population.
- Published
- 2018
- Full Text
- View/download PDF
5. Relationship between brachial-ankle and heart-femoral pulse wave velocities and the rapid decline of kidney function.
- Author
-
Lee SW, Han SH, Yoo TH, Chung W, Park SK, Chae DW, Ahn C, and Oh KH
- Subjects
- Adult, Aged, Chronic Disease, Disease Progression, Female, Glomerular Filtration Rate, Humans, Korea, Male, Middle Aged, Prospective Studies, Brachial Artery, Femoral Artery, Kidney Diseases pathology, Pulse Wave Analysis
- Abstract
The impact of brachial-ankle pulse wave velocity (baPWV) and heart-femoral pulse wave velocity (hfPWV) on rapid decline of estimated glomerular filtration rate (eGFR) has been inconclusive. The database of a multicenter prospective study of 2238 patients in Korea enrolled from 2011 to 2016 was reviewed. After excluding patients with missing baPWV (n = 257) and eGFR change (n = 180), the study included 1801 non-dialysis chronic kidney disease (CKD) patients. The eGFR change <-5ml/min/1.73 m
2 /year was defined as rapid decline. During a mean of 2.2 years, the mean eGFR change was -3.6 ml/min/1.73 m2 /year, and 31.6% of patients were classified as having rapid decline. Older age, causes of CKD, increased heart rate, systolic blood pressures, and proteinuria were associated with the highest baPWV quintile. In multivariate logistic regression analyses, the odds of a rapid decline in eGFR was 1.9 times higher in the fifth quintile than in the first quintile (P = 0.013). In a subset with baPWV and hfPWV (n = 1182), high baPWV was associated with rapid eGFR decline only when accompanied by a high hfPWV. These findings suggest that central and peripheral PWVs may simultaneously affect rapid eGFR decline.- Published
- 2018
- Full Text
- View/download PDF
6. Selective tubular activation of hypoxia-inducible factor-2α has dual effects on renal fibrosis.
- Author
-
Kong KH, Oh HJ, Lim BJ, Kim M, Han KH, Choi YH, Kwon K, Nam BY, Park KS, Park JT, Han SH, Yoo TH, Lee S, Kim SJ, Kang DH, Choi KB, Eremina V, Quaggin SE, Ryu DR, and Kang SW
- Subjects
- Animals, Atrophy, Basic Helix-Loop-Helix Transcription Factors metabolism, Biomarkers, Disease Models, Animal, Disease Progression, Epithelial Cells metabolism, Fibrosis, Glomerulonephritis, IGA etiology, Glomerulonephritis, IGA metabolism, Glomerulonephritis, IGA pathology, Humans, Hypoxia genetics, Hypoxia metabolism, Kidney Diseases pathology, Kidney Function Tests, Kidney Tubules pathology, Male, Mice, Mice, Transgenic, Middle Aged, Basic Helix-Loop-Helix Transcription Factors genetics, Kidney Diseases etiology, Kidney Diseases metabolism, Kidney Tubules metabolism, Transcriptional Activation
- Abstract
Hypoxia-inducible factor (HIF) is a key transcriptional factor in the response to hypoxia. Although the effect of HIF activation in chronic kidney disease (CKD) has been widely evaluated, the results have been inconsistent until now. This study aimed to investigate the effects of HIF-2α activation on renal fibrosis according to the activation timing in inducible tubule-specific transgenic mice with non-diabetic CKD. HIF-2α activation in renal tubular cells upregulated mRNA and protein expressions of fibronectin and type 1 collagen associated with the activation of p38 mitogen-activated protein kinase. In CKD mice, activation of HIF-2α at the beginning of CKD significantly aggravated renal fibrosis, whereas it did not lead to renal dysfunction. However, activation at a late-stage of CKD abrogated both renal dysfunction and fibrosis, which was associated with restoration of renal vasculature and amelioration of hypoxia through increased renal tubular expression of VEGF and its isoforms. As with tubular cells with HIF-2α activation, those under hypoxia also upregulated VEGF, fibronectin, and type 1 collagen expressions associated with HIF-1α activation. In conclusion, late-stage renal tubular HIF-2α activation has protective effects on renal fibrosis and the resultant renal dysfunction, thus it could represent a therapeutic target in late stage of CKD.
- Published
- 2017
- Full Text
- View/download PDF
7. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development.
- Author
-
Kang HM, Ahn SH, Choi P, Ko YA, Han SH, Chinga F, Park AS, Tao J, Sharma K, Pullman J, Bottinger EP, Goldberg IJ, and Susztak K
- Subjects
- Animals, Epithelial Cells metabolism, Epithelial Cells pathology, Fatty Acids genetics, Fibrosis metabolism, Fibrosis pathology, Gene Expression Profiling, Gene Expression Regulation, Humans, Inflammation metabolism, Inflammation pathology, Kidney Diseases metabolism, Kidney Diseases pathology, Kidney Tubules metabolism, Kidney Tubules pathology, Mice, Oxidation-Reduction, Signal Transduction genetics, Fatty Acids metabolism, Fibrosis genetics, Inflammation genetics, Kidney Diseases genetics
- Abstract
Renal fibrosis is the histological manifestation of a progressive, usually irreversible process causing chronic and end-stage kidney disease. We performed genome-wide transcriptome studies of a large cohort (n = 95) of normal and fibrotic human kidney tubule samples followed by systems and network analyses and identified inflammation and metabolism as the top dysregulated pathways in the diseased kidneys. In particular, we found that humans and mouse models with tubulointerstitial fibrosis had lower expression of key enzymes and regulators of fatty acid oxidation (FAO) and higher intracellular lipid deposition compared to controls. In vitro experiments indicated that inhibition of FAO in tubule epithelial cells caused ATP depletion, cell death, dedifferentiation and intracellular lipid deposition, phenotypes observed in fibrosis. In contrast, restoring fatty acid metabolism by genetic or pharmacological methods protected mice from tubulointerstitial fibrosis. Our results raise the possibility that correcting the metabolic defect in FAO may be useful for preventing and treating chronic kidney disease.
- Published
- 2015
- Full Text
- View/download PDF
8. Preservation of renal function by thyroid hormone replacement therapy in chronic kidney disease patients with subclinical hypothyroidism.
- Author
-
Shin DH, Lee MJ, Kim SJ, Oh HJ, Kim HR, Han JH, Koo HM, Doh FM, Park JT, Han SH, Yoo TH, and Kang SW
- Subjects
- Adult, Aged, Blood Pressure, Chronic Disease, Female, Glomerular Filtration Rate, Humans, Hypothyroidism physiopathology, Iodide Peroxidase immunology, Kidney Diseases physiopathology, Male, Middle Aged, Thyrotropin blood, Hormone Replacement Therapy, Hypothyroidism drug therapy, Kidney Diseases complications, Thyroid Hormones therapeutic use
- Abstract
Context: Subclinical hypothyroidism is not a rare condition, but the use of thyroid hormone to treat subclinical hypothyroidism is an issue of debate., Objective: This study was undertaken to investigate the impact of thyroid hormone therapy on the changes in estimated glomerular filtration rate (eGFR) in subclinical hypothyroidism patients with stage 2-4 chronic kidney disease., Patients: A total of 309 patients were included in the final analysis., Main Outcome Measure: The changes in eGFR over time were compared between patients with and without thyroid hormone replacement therapy using a linear mixed model. Kaplan-Meier curves were constructed to determine the effect of thyroid hormone on renal outcome, a reduction of eGFR by 50%, or end-stage renal disease. The independent prognostic value of subclinical hypothyroidism treatment for renal outcome was ascertained by multivariate Cox regression analysis., Results: Among the 309 patients, 180 (58.3%) took thyroid hormone (treatment group), whereas 129 (41.7%) did not (nontreatment group). During the mean follow-up duration of 34.8 ± 24.3 months, the overall rate of decline in eGFR was significantly greater in the nontreatment group compared to the treatment group (-5.93 ± 1.65 vs. -2.11 ± 1.12 ml/min/yr/1.73 m(2); P = 0.04). Moreover, a linear mixed model revealed that there was a significant difference in the rates of eGFR decline over time between the two groups (P < 0.01). Kaplan-Meier analysis also showed that renal event-free survival was significantly lower in the nontreatment group (P < 0.01). In multivariate Cox regression analysis, thyroid hormone replacement therapy was found to be an independent predictor of renal outcome (hazard ratio, 0.28; 95% CI, 0.12-0.68; P = 0.01)., Conclusion: Thyroid hormone therapy not only preserved renal function better, but was also an independent predictor of renal outcome in chronic kidney disease patients with subclinical hypothyroidism.
- Published
- 2012
- Full Text
- View/download PDF
9. Removal of kidney stones by extracorporeal shock wave lithotripsy is associated with delayed progression of chronic kidney disease.
- Author
-
Yoo DE, Han SH, Oh HJ, Kim SJ, Shin DH, Lee MJ, Yoo TH, Kang SW, and Choi KH
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Glomerular Filtration Rate physiology, Humans, Male, Middle Aged, Retrospective Studies, Chronic Disease prevention & control, Kidney Calculi therapy, Kidney Diseases prevention & control, Lithotripsy methods
- Abstract
Purpose: This study aimed to elucidate whether stone removal by extracorporeal shock wave lithotripsy (ESWL) is associated with delayed chronic kidney disease (CKD) progression., Materials and Methods: We conducted a retrospective analysis of 131 nephrolithiasis patients with stage 3 and 4 CKD. We collected baseline clinical and laboratory data, kidney stone characteristics, and history of receiving ESWL. We classified study patients into two groups according to whether they underwent ESWL or not (Non-ESWL group vs. ESWL group). We initially compared annual estimated glomerular filtration rate (eGFR) changes of Non-ESWL group with those of ESWL group before undergoing ESWL. In the next step, we sought to compare annual eGFR changes in the same patients before and after ESWL. Finally, we compared annual eGFR changes between success and failure groups among patients undergoing ESWL., Results: The mean age of the patients was 62 years and 72.5% were male. The mean observation period was 3.2 years. Non-ESWL group and ESWL group before undergoing ESWL showed similar annual eGFR changes (-1.75±6.5 vs. -1.63±7.2 mL/min/1.73 m²/year, p=0.425). However, eGFR declined slower after undergoing ESWL than before ESWL (annual eGFR changes, -0.29±6.1 vs. -1.63±7.2 mL/min/1.73 m²/year, p<0.05). In addition, among patients in ESWL group, eGFR declined faster in the failure group than in the success group (annual eGFR change, -1.01±4.7 vs. -0.05±5.2 mL/min/1.73 m²/year, p<0.05)., Conclusion: Our results suggest that stone removal by ESWL is associated with delayed deterioration of renal function in CKD patients with nephrolithiasis.
- Published
- 2012
- Full Text
- View/download PDF
10. Relation of homocysteinemia to contrast-induced nephropathy in patients undergoing percutaneous coronary intervention.
- Author
-
Kim SJ, Choi D, Ko YG, Kim JS, Han SH, Kim BK, Kang SW, Hong MK, Jang Y, Choi KH, and Yoo TH
- Subjects
- Aged, Coronary Angiography adverse effects, Coronary Angiography methods, Female, Follow-Up Studies, Glomerular Filtration Rate drug effects, Humans, Hyperhomocysteinemia blood, Kidney Diseases blood, Male, Middle Aged, Myocardial Infarction blood, Myocardial Infarction therapy, Prognosis, Retrospective Studies, Time Factors, Triiodobenzoic Acids adverse effects, Angioplasty, Balloon, Coronary, Contrast Media adverse effects, Homocysteine blood, Hyperhomocysteinemia chemically induced, Kidney Diseases chemically induced, Myocardial Infarction diagnosis
- Abstract
Hyperhomocysteinemia induces oxidative stress and endothelial dysfunction, which share the proposed pathophysiologic mechanisms of contrast-induced nephropathy (CIN). However, no study has investigated the relation between hyperhomocysteinemia and CIN. The aim of the present study was to evaluate the effects of hyperhomocysteinemia on CIN in patients undergoing percutaneous coronary intervention. This was an observational cohort study that included 572 patients who underwent percutaneous coronary intervention. CIN was defined as an absolute ≥0.5 mg/dl or a relative ≥25% increase in the serum creatinine level at 48 hours after the procedure. The incidence of CIN was significantly greater in patients in the third homocysteine tertile (from lowest to highest, 4.7%, 7.3%, and 24.2%, p <0.001). Furthermore, the homocysteine levels were significantly greater in patients with CIN than in those without CIN (16.9 ± 4.9 vs 13.5 ± 4.2 μmol/L, p <0.001). In multiple logistic regression models, hyperhomocysteinemia was an independent risk factor for CIN (per the SD change in the plasma homocysteine level [4.44 μmol/L], odds ratio 1.70, 95% confidence interval 1.07 to 2.71, p = 0.025) after adjusting for major risk factors such as age, diabetes, and baseline cardiac and renal function. In subgroup analyses according to diabetes, acute coronary syndrome, or baseline estimated glomerular filtration rate, significant, graded associations were found between the homocysteine level and the incidence of CIN. In conclusion, hyperhomocysteinemia is independently associated with a greater risk of CIN in patients undergoing percutaneous coronary intervention., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
11. The 2021 KDIGO blood pressure target and the progression of chronic kidney disease: Findings from KNOW‐CKD.
- Author
-
Park, Cheol Ho, Kim, Hyung Woo, Park, Jung Tak, Chang, Tae Ik, Yoo, Tae‐Hyun, Park, Sue Kyung, Kim, Yaeni, Jung, Ji Yong, Jeong, Jong Cheol, Oh, Kook‐Hwan, Kang, Shin‐Wook, and Han, Seung Hyeok
- Subjects
CHRONIC kidney failure ,BLOOD pressure ,RENAL replacement therapy ,GLOMERULAR filtration rate ,KIDNEY diseases ,BULLOUS pemphigoid - Abstract
Background: The 2021 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure (BP) in chronic kidney disease (CKD) recommends a target systolic BP of <120 mmHg as this target can provide cardiovascular benefits. However, it remains unclear whether implementing the new BP target could improve kidney outcomes. Methods: The association between the 2021 KDIGO BP target and CKD progression was examined and compared with the 2012 KDIGO BP target among 1724 participants included in the KoreaN Cohort Study for Outcomes in Patients With CKD. The main exposure was the BP status categorized according to the 2012 or 2021 KDIGO guideline: (1) controlled within the 2021 target, (2) controlled within the 2012 target only, and (3) above both targets. The primary outcome was a composite kidney outcome of ≥50% decline in the estimated glomerular filtration rate from baseline or the initiation of kidney replacement therapy during the follow‐up period. Results: Composite kidney outcomes occurred in 650 (37.7%) participants during the 8078 person‐years of follow‐up (median, 4.9 years). The incidence rates of this outcome were 55, 66.5, and 116.4 per 1000 person‐years in BP controlled within the 2021 and 2012 KDIGO targets, and BP above both targets, respectively. In the multivariable cause‐specific hazard model, hazard ratios for the composite outcome were 0.76 (95% confidence interval (CI), 0.60–0.95) for BP controlled within the 2021 target and 1.36 (95% CI, 1.13–1.64) for BP above both targets, compared with BP controlled within 2012 target only. Conclusion: The newly lowered BP target by the 2021 KDIGO guideline was associated with improved kidney outcome compared with BP target by the 2012 KDIGO guideline. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Association Between Longitudinal Blood Pressure Trajectory and the Progression of Chronic Kidney Disease: Results From the KNOW-CKD.
- Author
-
Joo, Young Su, Kim, Hyung Woo, Nam, Ki Heon, Young Lee, Jee, Chang, Tae Ik, Park, Jung Tak, Yoo, Tae-Hyun, Lee, Joongyub, Kim, Soo Wan, Oh, Yun Kyu, Oh, Kook-Hwan, Kim, Yong-Soo, Ahn, Curie, Kang, Shin-Wook, and Han, Seung Hyeok
- Abstract
[Figure: see text]. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Low-dose aspirin was associated with an increased risk of cardiovascular events in patients with chronic kidney disease patients and low bodyweight: results from KNOW-CKD study.
- Author
-
Oh, Yun Jung, Kim, Ae Jin, Ro, Han, Chang, Jae Hyun, Lee, Hyun Hee, Chung, Wookyung, Hyun, Young Youl, Lee, Joongyub, Kim, Yeong Hoon, Han, Seung Hyeok, Chae, Dong-Wan, Ahn, Curie, Oh, Kook-Hwan, and Jung, Ji Yong
- Subjects
ASPIRIN ,CARDIOVASCULAR diseases ,BODY weight ,HEALTH outcome assessment ,KIDNEY diseases - Abstract
The benefits and risks of aspirin therapy for patients with chronic kidney disease (CKD) who have a high burden of cardiovascular events (CVE) are controversial. To examine the effects of low-dose aspirin on major clinical outcomes in patients with CKD. As a prospective observational cohort study, using propensity score matching, 531 aspirin recipients and non-recipients were paired for analysis from 2070 patients and fulfilled the inclusion criteria among 2238 patients with CKD. The primary outcome was the first occurrence of major CVE. The secondary outcomes were kidney events defined as a > 50% reduction of estimated glomerular filtration rate from baseline, doubling of serum creatinine, or onset of kidney failure with replacement therapy, the all-cause mortality, and bleeding event. The incidence of CVE was significantly greater in low-dose aspirin users than in non-users (HR 1.798; P = 0.011). A significant association between aspirin use and an increased risk of CVE was observed only in the lowest quartile of body weight (HR 4.014; P = 0.019) (Q1 < 60.0 kg). Secondary outcomes were not significantly different between aspirin users and non-users. It needs to be individualized of prescribing low-dose aspirin for the prevention of cardiovascular events in patients with chronic kidney disease, particularly patients with low bodyweight (< 60 kg). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Arterial Stiffness as a Risk Factor for Subclinical Coronary Artery Calcification in Predialysis Chronic Kidney Disease: From the KNOW-CKD Study.
- Author
-
Hyun, Young Youl, Kim, Hyang, Oh, Kook-Hwan, Ahn, Curie, Park, Sue K., Chae, Dong Wan, Han, Seung Hyeok, Kim, Yong-Soo, Lee, Sung Woo, Kim, Chang Seong, and Lee, Kyu-Beck
- Subjects
ARTERIAL diseases ,CORONARY arteries ,CORONARY artery calcification ,CHRONIC diseases ,KIDNEY diseases ,DISEASE risk factors - Abstract
Background/Aims: Both arterial stiffness and coronary artery calcification (CAC) are important predictors of cardiovascular disease in the general population and in chronic kidney disease (CKD) patients. Recent studies on arterial stiffness and CAC in subjects with preserved renal function have verified the association between the two. However, the relationship is not well evaluated in CKD patients. Methods: This cross-sectional study analyzed 1,385 predialysis CKD patients from the KNOW-CKD cohort. Participants were divided into four groups according to brachial-ankle pulse wave velocity (baPWV) quartile. Coronary artery calcium scores (CACS) were assessed using cardiac computed tomography and CAC was defined as a CACS >100. Results: CAC prevalence was higher in the higher baPWV groups (6.4, 9.8, 23.7, and 43.8% for the 1st to 4th quartiles of baPWV, respectively, p < 0.001). In Tobit regression analyses that were fully adjusted for traditional and renal cardiovascular risk factors, the CACS ratio comparing the highest and lowest baPWV quartiles was 3.03 (95% CI, 1.59–6.87). Similarly, the OR for CAC in the highest baPWV quartile compared to the lowest quartile was 1.98 (95% CI, 1.09–3.60) in a fully adjusted multivariate logistic model. Results were consistent across analyses with different cutoffs for CAC or with different clinically relevant subgroups. Conclusion: Increased arterial stiffness measured by high baPWV was associated with CAC in a predialysis CKD cohort. Longitudinal studies are needed to determine the effect of arterial stiffness on the development or progression of CAC in CKD. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Body Mass Index, waist circumference, and health-related quality of life in adults with chronic kidney disease.
- Author
-
Hyun, Young Youl, Lee, Kyu-Beck, Chung, Wookyung, Kim, Yong-Soo, Han, Seung Hyeok, Oh, Yun Kyu, Chae, Dong-Wan, Park, Sue Kyung, Oh, Kook-Hwan, Ahn, Curie, and KNOW-CKD Study Investigator
- Subjects
QUALITY of life ,WAIST circumference ,BODY mass index ,KIDNEY diseases ,CHRONIC diseases - Abstract
Purpose: Obesity is linked to poor health-related quality of life (HRQOL) in the general population, but its role in chronic kidney disease (CKD) is uncertain.Methods: We conducted a cross-sectional study that investigated 1880 participants from the KoreaN cohort study for Outcome in patients With CKD (KNOW-CKD) who underwent complete baseline laboratory tests, health questionnaires, and HRQOL. HRQOL was assessed by physical component summary (PCS) and mental component summary (MCS) of the SF-36 questionnaire. We used multivariable linear regression models to examine the relationship between Body Mass Index (BMI) and sex-specific waist circumference (WC) with HRQOL.Results: Adults with higher BMI and greater WC showed lower PCS. After adjusting for age, sex, socioeconomic state, comorbidities, and laboratory findings, we found that WC, but not BMI, was associated with PCS. Greater WC quintiles were associated with lower PCS [WC-4th quintile (β, - 2.63, 95% CI - 5.19 to - 0.06) and WC-5th quintile (β, - 3.71, 95% CI - 6.28 to - 1.15)]. The association between WC and PCS was more pronounced in older adults, woman, patients with diabetes, cardiovascular disease, or lower eGFR. The relationship between BMI and WC with MCS was not significant.Conclusions: In adults with CKD, WC is a better indicator of poor physical HRQOL than BMI. The association between WC and physical HRQOL is modified by age, sex, eGFR, and comorbidities such as diabetes and cardiovascular disease. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
16. Clinical Significance of Crescent Formation in IgA Nephropathy – a Multicenter Validation Study.
- Author
-
Park, Sehoon, Baek, Chung Hee, Park, Su-Kil, Kang, Hee Gyung, Hyun, Hye Sun, Park, Eujin, Han, Seung Hyeok, Ryu, Dong-Ryeol, Kim, Dong Ki, Oh, Kook-Hwan, Joo, Kwon Wook, Kim, Yon Su, Moon, Kyung Chul, Chin, Ho Jun, and Lee, Hajeong
- Subjects
IGA glomerulonephritis ,KIDNEY diseases ,CHRONIC kidney failure ,GLOMERULAR filtration rate ,REGRESSION analysis - Abstract
Background/Aims: Additional validation study was warranted to confirm the clinical significance of C score, which was recently added to the Oxford classification for immunoglobulin A nephropathy (IgAN). Methods: We performed a multicenter retrospective cohort study in four hospitals in Korea. Patients who had biopsied glomeruli less than eight or inadequate follow-up information were excluded. Clinicopathologic parameters, including the degree of cellular or fibrocellular crescents, were collected and included in multivariable models for Cox regression analysis. The main outcome was a composite renal outcome, defined as a merge of progression to end-stage renal disease (ESRD) and halving of estimated glomerular filtration rate (eGFR) from baseline. Results: Among included 3,380 biopsy-confirmed IgAN patients, there were 664 (19.6%) patients with C1 and 60 (1.8%) patients with C2 scores in the study population. Although C0 and C1 patients shared similar baseline characteristics, C2 patients frequently had more clinicopathologic risk factors for poor prognosis of IgAN. Both C1 [adjusted HR 1.33 (1.11-1.58), P=0.002] and C2 [adjusted HR 2.24 (1.46-3.43), P< 0.001] scores were associated with an increased risk of the composite outcome. C2 was a strong predictive parameter associated with both progression to ESRD and halving of eGFR, whereas C1 was mainly associated with the increased risk of halving of eGFR. Notably, the proportion of crescent showed a linear association with the risk of adverse renal outcome. Conclusion: The C score in the Oxford classification is a valid predictive parameter for IgAN prognosis. Additional clinical attention is necessary for IgAN patients with identified cellular or fibrocellular crescents. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Changes in obese metabolic phenotypes over time and risk of incident chronic kidney disease.
- Author
-
Nam, Ki Heon, Yun, Hae‐Ryong, Joo, Young Su, Kim, Joohwan, Lee, Sangmi, Lee, Changhyun, Park, Kyoung Sook, Park, Jung Tak, Chang, Tae‐Ik, Kang, Ea Wha, Yoo, Tae‐Hyun, Kang, Shin‐Wook, and Han, Seung Hyeok
- Subjects
KIDNEY diseases ,OBESITY ,METABOLISM ,GLOMERULAR filtration rate ,PHENOTYPES - Abstract
Aim: To examine the association between metabolically healthy obese (MHO) phenotype and incident chronic kidney disease (CKD) and study whether changes in metabolic phenotypes over time could affect CKD risk. Methods: A total of 8589 subjects from the Korean Genome and Epidemiology Study were categorized into four groups based on the presence of obesity and metabolic abnormalities (MA). The primary endpoint was an onset of incident CKD defined as an estimated glomerular filtration rate of ≤ 60 mL/min/1.73 m2. Multivariable Cox analysis and time‐varying Cox analysis were performed to delineate the relationship between obese metabolic phenotypes and incident CKD after adjustment for sociodemographic factors and clinical and laboratory parameters. Results: During a mean follow‐up duration of 9.3 years, CKD occurred in 782 (9.1%) participants. In the multivariable Cox model, the hazard ratio (HR) for incident CKD in the MHO, metabolically abnormal non‐obese (MANO), and metabolically abnormal obese (MAO) groups was 1.42 (P = 0.002), 1.45 (P < 0.001), and 1.77 (P < 0.001), respectively, compared with the metabolically healthy non‐obese (MHNO) group. Time‐varying analysis with these four phenotypes as time‐varying exposures showed the same results. Furthermore, subjects with persistent MHO through follow‐up were at a 2.0‐fold increased risk of CKD (P < 0.001). 41.0% of subjects experienced phenotype changes during follow‐up. Over the long term, the MHO group had a higher proportion of transition to the MA phenotype and unfavourable metabolic profiles than the MHNO group. Among MHO subjects, those who transitioned to MAO were at a 4.1‐fold increased risk of incident CKD than those who regressed to MHNO. In addition, transition to MHO from other groups carried a higher risk of CKD than persistent MHNO. Conclusion: MHO subjects are at increased risk for incident CKD. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. Vitamin D deficiency is significantly associated with depression in patients with chronic kidney disease.
- Author
-
Jhee, Jong Hyun, Kim, Hyoungnae, Park, Seohyun, Yun, Hae-Ryong, Jung, Su-Young, Kee, Youn Kyung, Yoon, Chang-Yun, Park, Jung Tak, Han, Seung Hyeok, Kang, Shin-Wook, and Yoo, Tae-Hyun
- Subjects
PREVENTION of mental depression ,KIDNEY diseases ,VITAMIN D deficiency ,LOGISTIC regression analysis ,PSYCHOLOGICAL research ,PATIENTS - Abstract
Background: Depression is reported to be the most common psychological problem in patients with chronic kidney disease (CKD). Several studies have reported that lower levels of serum vitamin D are significantly associated with depression. Both vitamin D deficiency and depression are prevalent in patients with CKD, yet the relationship between these two factors remains poorly understood. This study aimed to investigate the association between vitamin D levels and depression among CKD patients. Methods: Totally, 21,257 individuals who participated in the Korean National Health and Nutrition Examination Survey (KNHANES V, VI) from 2010–2014 were screened for the study; 533 CKD patients were included. Vitamin D deficiency was defined as serum 25-hydroxyvitamin D3 [25(OH)D3] ≤10 ng/mL. Patients were divided into vitamin D deficient or sufficient groups. Depression was screened for using the Korean version of the WHO Composite International Diagnostic Interview-Short Form. The association between vitamin D deficiency and depression was evaluated by multivariate logistic regression analysis. Results: The mean participant age was 70.1±9.4 years; 262 patients (49.2%) were male. The median 25(OH)D
3 level was 19.1±6.9 ng/mL. The prevalence of depression was higher in CKD patients than in the general population (14.3 vs. 11.1%, P = 0.03). Additionally, the prevalence of depression was significantly higher in CKD patients with (vs. without) vitamin D deficiency (32.5% vs. 50.0%, P<0.001). Multivariate logistic regression analysis showed that vitamin D deficiency was a significant independent predictor of depression after adjusting for confounding factors (adjusted odds ratio, 6.15; 95% confidence interval, 2.02–8.75; P = 0.001). Conclusion: Depression was highly prevalent in CKD patients, in whom vitamin D deficiency was a significant independent predictor of depression. Therefore, management of vitamin D deficiency might help prevent depression in CKD patients. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
19. Albuminuria as a Risk Factor for Anemia in Chronic Kidney Disease: Result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).
- Author
-
Han, Ji Suk, Lee, Mi Jung, Park, Kyoung Sook, Han, Seung Hyeok, Yoo, Tae-Hyun, Oh, Kook-Hwan, Park, Sue Kyung, Lee, Joongyub, Hyun, Young Youl, Chung, Wookyung, Kim, Yeong Hoon, Ahn, Curie, and Choi, Kyu Hun
- Subjects
KIDNEY diseases ,ALBUMINURIA ,ANEMIA ,COHORT analysis ,KOREANS ,HEALTH outcome assessment ,PATIENTS ,DIAGNOSIS ,DISEASE risk factors ,DISEASES - Abstract
Background: Anemia is a common complication among patients with chronic kidney disease (CKD), and it is associated with unfavorable clinical outcomes in patients with CKD independent of the estimated glomerular filtration rate (eGFR). We assessed the association of the urinary albumin-to-creatinine ratio (ACR) and eGFR with anemia in CKD patients. Methods: We conducted a cross-sectional study using baseline data from the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD). Multiple regression analysis was performed to identify the independent association of albuminuria with anemia. Furthermore, odds ratios for anemia were calculated by cross-categorization of ACR and eGFR. Results: Among 1,456 patients, the mean age was 53.5 ± 12.4 years, and the mean eGFR and ACR were 51.9 ± 30.5 mL/min per 1.73 m
2 and 853.2 ± 1,330.3 mg/g, respectively. Anemia was present in 644 patients (40.5%). Multivariate analysis showed that the odds ratio of anemia increased according to ACR levels, after adjusting for age, sex, eGFR, body mass index, pulse pressure, cause of CKD, use of erythropoiesis stimulating agents, serum calcium and ferritin (ACR < 30 mg/g as a reference group; 30–299 mg/g, adjusted odds ratio (OR) = 1.43, 95% confidence interval (CI) = 0.88–2.33; ≥300 mg/g, adjusted OR = 1.86, 95% CI = 1.12–3.10). In addition, graded associations were observed in cross-categorized groups of a higher ACR and eGFR compared to the reference group with an ACR <30 mg/g and eGFR ≥60 mL/min per 1.73 m2 . Conclusion: The present study demonstrated that albuminuria was a significant risk factor for anemia in CKD patients independent of the eGFR. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
20. Optimal Proteinuria Target for Renoprotection in Patients with IgA Nephropathy.
- Author
-
Nam, Ki Heon, Kie, Jeong Hae, Lee, Mi Jung, Chang, Tae-Ik, Kang, Ea Wha, Kim, Dong Wook, Lim, Beom Jin, Park, Jung Tak, Kwon, Young Eun, Kim, Yung Ly, Park, Kyoung Sook, An, Seong Yeong, Oh, Hyung Jung, Yoo, Tae-Hyun, Kang, Shin-Wook, Choi, Kyu Hun, Jeong, Hyeon Joo, Han, Dae-Suk, and Han, Seung Hyeok
- Subjects
PROTEINURIA ,IGA glomerulonephritis ,KIDNEY diseases ,GLOMERULAR filtration rate ,CREATININE ,RETROSPECTIVE studies - Abstract
Background: Proteinuria is a target for renoprotection in kidney diseases. However, optimal level of proteinuria reduction in IgA nephropathy (IgAN) is unknown. Methods: We conducted a retrospective observational study in 500 patients with biopsy-proven IgAN. Time-averaged proteinuria (TA-P) was calculated as the mean of every 6 month period of measurements of spot urine protein-to-creatinine ratio. The study endpoints were a 50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD), and slope of eGFR. Results: During a median follow-up duration of 65 (12–154) months, a 50% decline in eGFR occurred in 1 (0.8%) patient with TA-P of <0.3 g/g compared to 6 (2.7%) patients with TA-P of 0.3–0.99 g/g (hazard ratio, 2.82; P = 0.35). Risk of reaching a 50% decline in eGFR markedly increased in patients with TA-P of 1.0–2.99 g/g (P = 0.002) and those with TA-P≥3.0 g/g (P<0.001). ESRD did not occur in patients with TA-P<1.0 g/g compared to 26 (20.0%) and 8 (57.1%) patients with TA-P of 1.0–2.99 and ≥3.0 g/g, respectively. Kidney function of these two groups deteriorated faster than those with TA-P<1.0 g/g (P<0.001). However, patients with TA-P of 0.3–0.99 g/g had a greater decline of eGFR than patients with TA-P<0.3 g/g (−0.41±1.68 vs. −0.73±2.82 ml/min/1.73 m
2 /year, P = 0.03). Conclusion: In this study, patients with TA-P<1.0 g/g show favorable outcomes. However, given the faster eGFR decline in patients with TA-P of 0.3–0.99 g/g than in patients with TA-P<0.3 g/g, the ultimate optimal goal of proteinuria reduction can be lowered in the management of IgAN. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
21. Clinical implication of crescentic lesions in immunoglobulin A nephropathy.
- Author
-
Lee, Mi Jung, Kim, Seung Jun, Oh, Hyung Jung, Ko, Kwang Il, Koo, Hyang Mo, Kim, Chan Ho, Doh, Fa Mee, Yoo, Tae-Hyun, Kang, Shin-Wook, Choi, Kyu Hun, Lim, Beom Jin, Jeong, Hyeon Joo, and Han, Seung Hyeok
- Subjects
PRECANCEROUS conditions ,IMMUNOGLOBULIN A ,KIDNEY diseases ,ADVERSE health care events ,DEMOGRAPHIC change ,POPULATION aging ,SOCIOECONOMICS - Abstract
Background To date, there has been much controversy about the role of crescentic lesion as a significant prognostic factor in immunoglobulin A nephropathy (IgAN). This study evaluated whether crescentic lesions predict adverse renal outcomes in IgAN patients. Methods A total of 430 patients with biopsy-proven IgAN between January 2000 and December 2009 were included. Histological variables of the Oxford classification (Oxford-MEST) and the presence of crescents were assessed. The primary endpoint was a 50% decline in estimated glomerular filtration rate. Results Of the 430 patients, 81 (18.8%) had a crescentic lesion. During a mean follow-up of 61 months, the primary outcome occurred in 19 (23.5%) patients with crescents compared with 40 (11.5%) patients without crescents (P = 0.01). A Kaplan–Meier plot showed that the 10-year renal survival rate was significantly lower in patients with crescents than patients without crescents (P = 0.01). However, in a multivariable Cox analysis which included clinical factors and the Oxford-MEST, crescents were not significantly associated with an increased risk of developing the primary outcome [hazard ratio: 0.71, 95% confidence interval (CI) 0.36–1.41, P = 0.33]. Furthermore, adding crescents to the Oxford-MEST did not improve the discriminative ability for the prediction of renal outcomes [c-statistic: 0.86 (0.81–0.91) vs. 0.86 (0.80–0.91), P = 0.21]. Conclusion Crescentic lesion was not an independent prognostic factor, suggesting that crescents have limited value in predicting renal outcomes of IgAN. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
22. Thyroid Hormone Replacement Therapy Attenuates the Decline of Renal Function in Chronic Kidney Disease Patients with Subclinical Hypothyroidism.
- Author
-
Shin, Dong Ho, Lee, Mi Jung, Lee, Hye Sun, Oh, Hyung Jung, Ko, Kwang Il, Kim, Chan Ho, Doh, Fa Mee, Koo, Hyang Mo, Kim, Hyoung Rae, Han, Jae Hyun, Park, Jung Tak, Han, Seung Hyeok, Yoo, Tae-Hyun, and Kang, Shin-Wook
- Subjects
HYPOTHYROIDISM ,THYROID diseases ,KIDNEY diseases ,DYSLIPIDEMIA ,PATIENTS ,THERAPEUTICS - Abstract
Background: Subclinical hypothyroidism (SCH) is not a rare condition in females, the elderly, or patients with chronic kidney disease (CKD). Even though previous studies have demonstrated that thyroid hormone replacement therapy (THRT) improves cardiac function and dyslipidemia in patients with SCH, it remains unclear as to whether THRT can improve renal function in CKD patients with SCH. This study investigated the impact of THRT on changes in estimated glomerular filtration rates (eGFR) in this patient population. Methods: A total of 113 CKD patients with SCH who were treated with L-thyroxine and had eGFR available for at least 24 months before and after THRT were enrolled between January 2005 and December 2011. A linear mixed model was used to compare patients' clinical and biochemical parameters at various time points. The slope of the decline in eGFR over time, both before and after THRT, was also calculated and compared using a linear mixed model. Results: The mean age of the study participants was 63.2±12.7 years, and 36 patients (31.9%) were men. The mean follow-up duration before and after THRT was 28.6±4.5 and 30.6±6.4 months respectively. After 24 months of THRT, serum thyrotropin (TSH) levels were significantly reduced-8.86±0.49 versus 1.41±0.73 μIU/mL, p<0.001-but there were no significant changes in triiodothyronine and free thyroxine concentrations. Serum albumin, calcium, phosphate, cholesterol, and triglyceride levels were also comparable before and after THRT. The rates of decline in eGFR were significantly attenuated by THRT (−4.31±0.51 vs.−1.08±0.36 [mL/min]/[year·1.73 m
2 ], p<0.001), even after adjustment for age, sex, diabetes, mean arterial pressure, and serum albumin, cholesterol, and triglyceride concentrations ( p<0.001). Conclusion: THRT attenuated the rate of decline in renal function in CKD patients with SCH, suggesting that THRT may delay reaching end-stage renal disease in these patients. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
23. A case of membranous nephropathy as a manifestation of graft-versus-host disease
- Author
-
Han, Jae Hyun, Kim, Hyoung Rae, Kim, Gi Jeong, Lim, Beom Jin, Jeong, Hyeon Joo, Oh, Hyung Jung, Yoo, Tae-Hyun, Kang, Shin-Wook, Choi, Kyu Hun, and Han, Seung Hyeok
- Subjects
KIDNEY diseases ,GRAFT versus host disease ,NEPHROTIC syndrome ,HEMATOPOIETIC stem cell transplantation ,APLASTIC anemia ,HLA histocompatibility antigens ,CANCER chemotherapy ,RENAL biopsy - Abstract
Abstract: Nephrotic syndrome (NS) rarely occurs after hematopoietic stem cell transplantation (HSCT) as a late manifestation of graft-versus-host disease (GVHD). Herein, we report a case of HSCT-associated membranous nephropathy in a female patient with aplastic anemia. The patient received an allogeneic HSCT from her human leukocyte antigen-identical brother following myeloablative conditioning chemotherapy. NS occurred 21 months after HSCT without any concurrent features of chronic GVHD. The patient was treated with prednisolone and cyclosporine after renal biopsy confirmed membranous nephropathy, and achieved complete remission. Our report contradicts previous assumptions that concomitant chronic GVHD is responsible for the development of NS, suggesting that NS can develop as a new, independent manifestation of GVHD. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
24. Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis.
- Author
-
Han, Seung Hyeok, Kang, Ea Wha, Yoon, Se-Jung, Yoon, Hyang Sook, Lee, Hyun Chul, Yoo, Tae Hyun, Choi, Kyu Hun, Han, Dae-Suk, and Kang, Shin-Wook
- Subjects
- *
ANGIOTENSINS , *PERITONEAL dialysis , *KIDNEY diseases , *CLINICAL trials , *VALSARTAN , *ARTERIAL diseases , *HEALTH outcome assessment , *ENZYME inhibitors - Abstract
Background. Statins and angiotensin receptor blockers (ARBs) are known to improve vascular dysfunction in patients with chronic kidney disease. However, these effects have been inconsistent in dialysis patients. Moreover, it is currently unknown whether adding statins to ARBs improves vascular dysfunction better than ARB monotherapy in these patients.Methods. We conducted a prospective open randomized trial to investigate the effects of statin add-on to ARB on vascular protection in 124 nondiabetic patients undergoing peritoneal dialysis (PD). Initially, all patients received 80 mg/day of valsartan for 6 months. Excluding 10 patients who dropped out during this period, patients were randomly assigned to continue ARB treatment alone (n = 57) or to receive 10 mg/day of rosuvastatin (n = 57) added to ARB for the next 6 months. To assess vascular function, endothelium-dependent vasodilation and arterial stiffness were determined by brachial artery flow-mediated dilation (FMD) and brachial-ankle pulse wave velocity (baPWV), respectively.Results. Compared to baseline values, ARB treatment for the first 6 months significantly improved FMD% (2.97 ± 2.64 to 3.57 ± 2.58 %, P < 0.001). In addition, there was a small but significant decrease in baPWV during this period (1691.5 ± 276.3 to 1635.0 ± 278.6 cm/s, P = 0.048). After randomization, add-on treatment further improved FMD% (3.57 ± 2.73 to 4.24 ± 2.77 %, P = 0.003), whereas ARB monotherapy did not (P = 0.02 for between-group difference). Further slight improvement in baPWV (1617.0 ± 280.9 to 1528.9 ± 266.8 cm/s, P = 0.021) was observed only in the combined treatment group (P = 0.28 for between-group difference).Conclusions. Adding a statin to the ARB was of some help in improving vascular dysfunction more effectively than ARB monotherapy in nondiabetic PD patients. However, whether such limited improvements can lead to better clinical outcomes requires further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
25. Spontaneous remission of nephrotic syndrome in patients with IgA nephropathy.
- Author
-
Han, Seung Hyeok, Kang, Ea Wha, Park, Jeong Kyung, Kie, Jeong Hae, Han, Dae Suk, and Kang, Shin-Wook
- Subjects
- *
NEPHROTIC syndrome , *IMMUNOGLOBULIN A , *KIDNEY diseases , *PROTEINURIA , *ADRENOCORTICAL hormones , *CREATININE , *MEDICAL records - Abstract
Background. IgA nephropathy (IgAN) can be complicated by nephrotic syndrome. Because the spontaneous resolution of heavy proteinuria is rare, corticosteroid therapy should be considered in such cases, particularly when IgAN is combined with minimal-change disease. Here, we report our experience of spontaneous remission of nephrotic syndrome in patients with IgAN and the long-term outcomes of these patients.Methods. Two hundred and thirty-three patients with biopsy-proven IgAN were enrolled between January 2001 and March 2009. Demographic, clinical and laboratory data were collected retrospectively based on medical records. In addition, pathologic findings were reviewed for glomerular and tubulointerstitial lesions. Outcome data for complete or partial remission, spontaneous remission, relapse, deterioration of renal function, and end-stage renal disease were recorded.Results. Twenty-four patients (10.3%) presented nephrotic syndrome. Among them, five patients underwent spontaneous remission within 6 months after the presentation of nephrotic syndrome. Interestingly, spontaneous remission occurred even in two patients who had elevated serum creatinine levels and advanced renal damage. During follow-up, neither recurrence nor relapse occurred, and no patients showed progressive deterioration of kidney function.Conclusions. This study suggests that spontaneous remission of nephrotic syndrome may occur in any stage of IgAN and carries a favourable long-term outcome without relapse. Given the possibility of under-reported cases, large-scale studies are required, and careful attention should be paid to such complicated cases. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
26. Serum fibroblast growth factor–21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis.
- Author
-
Han, Seung Hyeok, Choi, Sung Hee, Cho, Bong Jun, Lee, Yenna, Lim, Soo, Park, Young Joo, Moon, Min Kyung, Lee, Hong Kyu, Kang, Shin-Wook, Han, Dae Suk, Kim, Young-Bum, Jang, Hak C., and Park, Kyong Soo
- Subjects
FIBROBLAST growth factors ,INSULIN resistance ,KIDNEY diseases ,SERUM ,PERITONEAL dialysis ,ANGIOTENSINS ,HOMEOSTASIS ,MULTIVARIATE analysis - Abstract
Abstract: Fibroblast growth factor–21 (FGF-21) is a new metabolic regulator, which is related to antiobesity and insulin sensitivity in vivo. However, the clinical implication of FGF-21 is poorly understood. To investigate whether FGF-21 may play a role as a metabolic regulator in patients with end-stage renal disease, we measured serum concentrations of FGF-21, inflammatory markers, and metabolic parameters in healthy people (n = 63) and nondiabetic patients receiving peritoneal dialysis (PD, n = 72). The patients were treated with angiotensin receptor blocker for 6 months, and the changes in FGF-21 concentration and metabolic parameters were assessed. Compared with controls, serum FGF-21 concentration was 8 times higher in patients undergoing PD (754.2 ± 463.5 vs 86.9 ± 60.2 pg/mL, P < .001). In controls, only lipid parameters correlated positively with FGF-21 concentration. In contrast, inflammatory markers (interleukin-6, fibrinogen, high-sensitivity C-reactive protein) and homeostasis model assessment of insulin resistance (HOMA-IR) correlated positively and residual renal function correlated inversely with serum FGF-21 concentration in PD patients. In a multivariate analysis adjusting these factors, residual renal function, HOMA-IR, and fibrinogen concentration were independent determinants of serum FGF-21 concentration. After 6-month angiotensin receptor blocker treatment, serum FGF-21 concentration declined significantly by 13% and HOMA-IR and inflammatory markers improved in PD patients. These findings suggest that FGF-21 may play a role in insulin resistance in patients with end-stage renal disease. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
27. Serum klotho is inversely associated with metabolic syndrome in chronic kidney disease: results from the KNOW-CKD study.
- Author
-
Kim, Hyo Jin, Lee, Joongyub, Chae, Dong-Wan, Lee, Kyu-Beck, Sung, Su Ah, Yoo, Tae-Hyun, Han, Seung Hyeok, Ahn, Curie, and Oh, Kook-Hwan
- Subjects
KIDNEY diseases ,POLYCYSTIC kidney disease ,METABOLIC syndrome ,RECEIVER operating characteristic curves ,CHRONIC diseases ,ENZYME-linked immunosorbent assay - Abstract
Background: Metabolic syndrome (MS) is prevalent in chronic kidney disease (CKD). Klotho, a protein linked to aging, is closely associated with CKD. Each component of MS and klotho has an association. However, little is known about the association between klotho and MS per se. We investigated the association between serum klotho levels and MS using baseline cross-sectional data obtained from a large Korean CKD cohort.Methods: Of the 2238 subjects recruited in the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD) between 2011 and 2016, 484 patients with missing data on serum klotho and extreme klotho values (values lower than the detectable range or > 6000 pg/mL) or with autosomal dominant polycystic kidney disease patients were excluded. The data of the remaining 1754 subjects were included in the present study. MS was defined using the revised National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III criteria. Serum klotho levels were measured using an enzyme-linked immunosorbent assay.Results: Mean patient age was 54.9 ± 12.1 years and 1110 (63.3%) were male. The prevalence of MS among all study subjects was 63.7% (n = 1118). The median serum klotho level was 527 pg/mL (interquartile range [IQR]: 418-656 pg/mL). Serum klotho level was significantly lower in MS patients than patients without MS (Median [IQR]; 521 pg/mL [413, 651] vs. 541 pg/mL [427, 676], respectively; P = 0.012). After adjusting for age, sex, estimated glomerular filtration rate, and overt proteinuria, serum klotho was independently associated with MS (adjusted odds ratio [OR], 0.44; 95% confidence interval, 0.23-0.82; P = 0.010). Furthermore, the adjusted OR for MS was found to be significantly increased at serum klotho levels of < 518 pg/mL (receiver operating characteristic curve cut-off value).Conclusions: Serum klotho was inversely associated with the presence of MS in patients with CKD.Trial Registration: This trial was registered on ClinicalTrials.gov on 26 June 2012 ( https://clinicaltrials.gov;NCT01630486 ). [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
28. The Reply.
- Author
-
Jhee, Jong Hyun and Han, Seung Hyeok
- Subjects
- *
CHRONIC kidney failure , *TUBERCULOSIS , *DOSE-response relationship in biochemistry , *GLOMERULAR filtration rate , *KIDNEY diseases , *COFFEE , *LONGITUDINAL method , *RESIDENTIAL patterns - Published
- 2019
- Full Text
- View/download PDF
29. The hyperglycemic and hyperinsulinemic combo gives you diabetic kidney disease immediately. Focus on "Combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney".
- Author
-
Han, Seung Hyeok and Susztak, Katalin
- Subjects
- *
DIABETIC nephropathies , *KIDNEY failure , *KIDNEY diseases , *HYPERGLYCEMIA , *GLUCOSE - Abstract
The article focuses on a study that discusses effect of acute combined hyperinsulinemic and hyperglycemic clamp on proinflammatory and profibrotic responses in the kidney. Topics discussed include Diabetic Kidney Disease (DKD) causes kidney failure, DKD caused by hyperglycemia (HG) due to reduce level of glycohemoglobin and increased level of urinary isoprostane levels causes renal oxidative stress. It also mentions that alteration level of glucose and insulin level has damaged the cells.
- Published
- 2014
- Full Text
- View/download PDF
30. A Low Serum Bicarbonate Concentration as a Risk Factor for Mortality in Peritoneal Dialysis Patients.
- Author
-
Chang, Tae Ik, Oh, Hyung Jung, Kang, Ea Wha, Yoo, Tae-Hyun, Shin, Sug Kyun, Kang, Shin-Wook, Choi, Kyu Hun, Han, Dae Suk, and Han, Seung Hyeok
- Subjects
SERUM ,BICARBONATE ions ,PERITONEAL dialysis ,ACIDOSIS ,KIDNEY diseases ,HEMODIALYSIS patients ,HEMODIALYSIS complications ,PATIENTS - Abstract
Background and Aim:Metabolic acidosis is common in patients with chronic kidney disease and is associated with increased mortality in hemodialysis patients. However, this relationship has not yet been determined in peritoneal dialysis (PD) patients. Methods:This prospective observational study included a total of 441 incident patients who started PD between January 2000 and December 2005. Using time-averaged serum bicarbonate (TA-Bic) levels, we aimed to investigate whether a low serum bicarbonate concentration can predict mortality in these patients. Results:Among the baseline parameters, serum bicarbonate level was positively associated with hemoglobin level and residual glomerular filtration rate (GFR), while it was negatively associated with albumin, C-reactive protein (CRP) levels, peritoneal Kt/V urea, and normalized protein catabolic rate (nPCR) in a multivariable linear regression analysis. During a median follow-up of 34.8 months, 149 deaths were recorded. After adjustment for age, diabetes, coronary artery disease, serum albumin, ferritin, CRP, residual GFR, peritoneal Kt/V urea, nPCR, and percentage of lean body mass, TA-Bic level was associated with a significantly decreased risk of mortality (HR per 1 mEq/L increase, 0.83; 95% CI, 0.76-0.91; p < 0.001). In addition, compared to patients with a TA-Bic level of 24-26 mEq/L, those with a TA-Bic level < 22 and between 22-24 mEq/L conferred a 13.10- and 2.13-fold increased risk of death, respectively. Conclusions:This study showed that a low serum bicarbonate concentration is an independent risk factor for mortality in PD patients. This relationship between low bicarbonate levels and adverse outcome could be related to enhanced inflammation and a more rapid loss of RRF associated with metabolic acidosis. Large randomized clinical trials to correct acidosis are warranted to confirm our findings. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
31. High serum adiponectin is associated with anemia development in chronic kidney disease: The results from the KNOW-CKD study.
- Author
-
Kim, Hyoungnae, Yun, Hae-Ryong, Park, Seohyun, Jhee, Jong Hyun, Park, Jung Tak, Yoo, Tae-Hyun, Lee, Kyu-Beck, Kim, Yeong-Hoon, Sung, Su-Ah, Lee, Joongyub, Kang, Shin-Wook, Choi, Kyu Hun, Ahn, Curie, and Han, Seung Hyeok
- Subjects
- *
ADIPONECTIN , *ANEMIA , *KIDNEY diseases , *HEMOGLOBINS , *GLOMERULAR filtration rate - Abstract
Background Adiponectin is an adipokine secreted by adipocytes. A low adiponectin level is a significant risk factor of diabetes mellitus and cardiovascular disease. Recent studies have shown that adiponectin is negatively associated with hematopoiesis and predicts the development of anemia in the general population. In chronic kidney disease (CKD) patients, circulating adiponectin level is paradoxically elevated and the role of adiponectin is complex. Therefore, we evaluated the relationship between adiponectin and anemia in these patients. Methods This prospective longitudinal study included 2113 patients from the KNOW-CKD study (KoreaN cohort study for Outcome in patients With CKD), after excluding 125 without data on adiponectin levels. Hemoglobin levels were measured yearly during a mean follow-up period of 23.7 months. Anemia was defined as hemoglobin levels of <13.0 and 12.0 g/dL for men and women, respectively. Results Mean patient age was 53.6 ± 12.2 years, and 1289 (61%) were men. The mean estimated glomerular filtration rate (eGFR) was 50.4 ± 30.2 mL min −1 1.73 m −2 . Serum adiponectin level was inversely associated with body mass index, eGFR, log-transformed C-reactive protein, and positively with Charlson comorbidity index, urine protein to creatinine ratio, and high density lipoprotein cholesterol. In addition, serum adiponectin level was also negatively correlated with hemoglobin level and reticulocyte production index in both men and women. In multivariable linear regression analysis after adjustment of multiple confounders, adiponectin was negatively associated with hemoglobin (men, β = −0.219, P < .001; women, β = −0.09, P = .025). Among 1227 patients without anemia at baseline, 307 newly developed anemia during the follow-up period. In multivariable Cox regression analysis after adjustment of confounders, high adiponectin level was significantly associated with an increased risk of incident anemia (per 1 µg/mL increase, hazard ratio, 1.02; 95% confidence interval 1.01–1.04; P = .001). Conclusions A high serum adiponectin level is independently associated with a low hemoglobin level and predicts the development of anemia in patients with CKD. These findings reveal the potential role of adiponectin in CKD-related anemia. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.